🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

20 recruiting trials

for Surufatinib

Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC NCT06876844Phase 21 site📍 Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jia… · Tests: combination of Surufatinib and Envolizumab Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer NCT07086456Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Surufatinib, Tislelizumab, Concurrent Chemotherapy, Radiotherapy Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer NCT05218889Phase 1, Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: surufatinib + camrelizumab + nab-paclitaxel + S-1, nab-paclitaxel + gemcitabine Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer NCT07436741Phase 31 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: surufatinib + gemcitabine + nab-paclitaxel, gemcitabine + nab-paclitaxel Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer NCT05652283Phase 21 site📍 Hefei Bai-Rong Xia · Tests: Pamiparib, Surufatinib Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer NCT06719700Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Chemotherapy, Immunotherapy, Angio-immuno kinase inhibitor, radiotherapy, Prophylactic Cranial Irradiation A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. NCT05747729Phase 1, Phase 21 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: Surufatinib and Serplulimab An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors NCT06038461Phase 1, Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Surufatinib Combined With Temozolomide and S-1 A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer NCT06361888Phase 2, Phase 352 sites📍 Hefei📍 Beijing📍 Beijing Hutchmed · Tests: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib w… Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer NCT06708858Phase 21 site📍 Beijing Dai, Guanghai · Tests: Surufatinib, Gemcitabine, Cisplatin, Durvalumab, Pembrolizumab A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer NCT05969171Phase 21 site📍 Shanghai Fudan University · Tests: Surufatinib, gemcitabine, nab-paclitaxel, Nab-paclitaxel, gemcitabine Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma NCT05472948Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Surufatinib, Sintilimab, Capecitabine Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07086469Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Neoadjuvant immunochemotherapy, Surufatinib Administration, Concurrent Chemotherapy, Radiotherapy Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC NCT07609121Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Radiotherapy, Concurrent chemotherapy, Tislelizumab, Surufatinib Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors NCT07357623Phase 24 sites📍 Hefei📍 Beijing📍 Zhengzhou Shanghai Chest Hospital · Tests: Surufatinib Combined With Standard chemotherapy, Surufatinib Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms NCT07272512Phase 44 sites📍 Shanghai📍 Shanghai📍 Shanghai Shanghai Zhongshan Hospital · Tests: Surufatinib Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria NCT07505472Phase 2, Phase 31 site📍 Changchun The First Hospital of Jilin University · Tests: Experimental Group, Control group Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer NCT06437353Phase 21 site📍 Hefei Anhui Provincial Cancer Hospital · Tests: Paclitaxel The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma NCT05839275Phase 1, Phase 21 site📍 Shanghai Fudan University · Tests: Surufatinib, Sintilimab, Radiotherapy Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) NCT05165407Phase 22 sites📍 Beijing📍 Beijing Peking University · Tests: Sintilimab, IBI310, Surufatinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy